In Vitro Studies Regarding the Safety of Chitosan and Hyaluronic Acid-Based Nanohydrogels Containing Contrast Agents for Magnetic Resonance Imaging

Int J Mol Sci. 2022 Mar 17;23(6):3258. doi: 10.3390/ijms23063258.

Abstract

The aim of this study was to investigate the biocompatibility of contrast agents, such as gadolinium 1, 4, 7, 10 tetraazacyclo-dodecane tetraacetic acid (GdDOTA) and gadolinium dioctyl terephthalate (GdDOTP), encapsulated in a polymeric matrix containing chitosan and hyaluronic acid using RAW264.7 murine macrophages and human blood samples. The cell viability and cytotoxicity were evaluated by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) and lactate dehydrogenase (LDH) assays, while cell cycle analysis was determined in RAW264.7 cells using flow cytometry. The mitochondrial membrane potential (MMP), hemolytic index, complement activation, and thrombogenic potential of gadolinium (Gd) containing nanohydrogels were measured by fluorometric and spectrophotometric methods. Taken together, our results demonstrate the good bio- and hemocompatibility of chitosan-based nanohydrogels with the RAW264.7 cell line and human blood cells, suggesting that these could be used as injectable formulations for the magnetic resonance imaging diagnostic of lymph nodes.

Keywords: RAW 264.7 cell line; biocompatibility; chitosan; contrast agents; hemocompatibility; nanohydrogel.

MeSH terms

  • Animals
  • Chitosan*
  • Contrast Media*
  • Gadolinium
  • Humans
  • Hyaluronic Acid
  • Magnetic Resonance Imaging / methods
  • Mice

Substances

  • Contrast Media
  • Hyaluronic Acid
  • Chitosan
  • Gadolinium